Feedback / Questions
Rezurock (belumosudil) - Romeck Pharma, Sanofi
Rezurock: Regulatory decision in EU for cGVHD in H2 2025
(Sanofi)
-
Jan 30, 2025 -
Q4 & FY2024 Results
EMA approval
•
Chronic Graft versus Host Disease • Graft versus Host Disease
https://www.sanofi.com/assets/dotcom/content-app/events/quaterly-results/2025/2024-q4-and-full-year-2024-results/2025-01-30_Sanofi-Q4FY-2024.pdf
Jan 30, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious